![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 48, 33847-33850, November 26, 1999
From the Friedrich Miescher-Institut, Maulbeerstrasse
66, CH-4058 Basel, Switzerland
Ndr is a nuclear serine/threonine protein kinase
that belongs to a subfamily of kinases implicated in the regulation of
cell division and cell morphology. This subfamily includes the kinases LATS, Orb6, Cot-1, and Dbf2. We show here that Ndr is potently activated when intact cells are treated with okadaic acid, suggesting that Ndr is normally held in a state of low activity by protein phosphatase 2A. We mapped the regulatory phosphorylation sites of Ndr
protein kinase and found that active Ndr is phosphorylated on Ser-281
and Thr-444. Mutation of either site to alanine strongly reduced both
basal and okadaic acid-stimulated Ndr activity, while combined mutation
abolished Ndr activity completely. Importantly, each of these sites
(and also the surrounding sequences) are conserved in the kinase
relatives of Ndr, suggesting a general mechanism of activation for
kinases of this subfamily. Ser-281 and Thr-444 are also similar to the
regulatory phosphorylation sites in several targets of the
phosphoinositide-dependent protein kinase
PDK1.1 However, PDK1
does not appear to function as an upstream kinase for Ndr. Thus, Ndr
and its close relatives may operate in a novel signaling pathway
downstream of an as-yet-unidentified kinase with specificity similar
to, but distinct from, PDK1.
Human Ndr is a nuclear serine/threonine protein kinase that has
been highly conserved during evolution and which is expressed in almost
all cell types of the body (1). Sequence comparisons show that, within
the protein kinase superfamily, Ndr is most closely related to a
subgroup of kinases known to be important in the control of cell
growth, cell division, and cell morphology. This subgroup is
exemplified by the kinases LATS, Orb6, Cot-1 (50-60% catalytic domain
identity with Ndr) and Dbf2 (40% catalytic domain identity with
Ndr). Several indications suggest that kinases of this type function,
either directly or indirectly, as negative regulators of
cyclin/cyclin-dependent kinase complexes. The mammalian LATS kinase (also called Wts) is the product of a tumor suppressor gene
and possesses an NH2-terminal domain that is able to
directly interact with and inhibit Cdc2 (2, 3). Consistent with this, LATS interacts genetically with Cdc2 in Drosophila. Orb6
overexpression delays the onset of mitosis in fission yeast, and this
effect is dependent upon the presence of a functional Wee1 protein,
implying that Orb6 can signal through Wee1 to down-regulate Cdc2
activity (4). Dbf2 is part of a network of genes required for
down-regulation of Cdc28-cyclin B at the end of mitosis in the budding
yeast S. cerevisiae (5). Dbf2 is transiently
activated at the metaphase/anaphase transition, coincident with changes
in its phosphorylation status, and mutation of Dbf2 causes cells
to arrest in late mitosis with high Cdc28 activity (6). Finally, the
Cot-1 protein of Neurospora crassa is required for hyphal
elongation, although it is not known how Cot-1 functions in this
process (7). Ndr thus belongs to a subfamily of kinases that are
important in cell growth control. Because of the high degree of
homology between the members of this kinase subgroup, it is probable
that they share, at least to some extent, related substrates and that
they are subject to similar regulation.
In the current work, we have analyzed the regulation of Ndr protein
kinase with regard to phosphorylation. Although some members of the
kinase family to which Ndr belongs are known to exist as phosphoproteins, their putative regulatory phosphorylation sites have
not been mapped. We demonstrate here that the kinase activity of Ndr
depends upon phosphorylation of Ndr on two sites, Ser-281 and Thr-444.
Both of these sites, as well as the sequences surrounding them, are
highly conserved in LATS, Orb6, and Cot-1 and are also present (albeit
with slightly lower homology) in Dbf2. Ser-281 and Thr-444 of
Ndr are also similar to phosphorylation sites in several PDK1
substrates, but despite this Ndr does not appear to be a target of
PDK1. Thus, Ndr and its kinase relatives may be regulated by an
upstream kinase distinct from PDK1, but with PDK1-like specificity.
Cell Culture--
COS-1 and 293 cells were transfected as
described previously (8, 9). Cells were treated for 1 h with 1 µM okadaic acid (Alexis Corp.) or with solvent alone
(0.8% N,N-dimethylformamide) in serum-containing medium.
Alternatively, cells were starved in Dulbecco's modified Eagle's
medium lacking serum for 24 h and then stimulated with 100 nM insulin or 50 ng/ml IGF-1 (Roche Molecular Biochemicals)
for 10 min. The following plasmids were used for transfection:
pECE.HA-Ndr-WT (10), pcDNA3.HA-Ndr-WT, and various derivative
plasmids encoding phosphorylation site mutants (see below),
pCMV5.myc-PDK1 (11) and pECE.HA- Purification of HA-Ndr--
Extracts from transfected COS-1
cells (10-15 mg of protein) were mixed with ~200 µg of 12CA5
prebound to 100 µl of protein A-Sepharose beads. After washing, bound
proteins were eluted with 1 ml of buffer containing 50 mM
Tris-HCl, pH 7.5, 0.1% NP-40, 4 µM leupeptin, 1 mM benzamidine, 1 µM microcystin, and 1 mg/ml HA peptide (YPYDVPDYA) and then precipitated by the addition of 125 µg/ml sodium deoxycholate and 10% trichloroacetic acid (13). Precipitated proteins were run on a 7.5% preparative
SDS-polyacrylamide gel which was then stained with Coomassie Blue.
Bands corresponding to HA-Ndr were excised.
Mass Spectrometry--
HA-Ndr in gel slices was reduced with
dithiothreitol, alkylated with iodoacetamide, and digested with trypsin
(14). NanoESI mass spectrometry (ESI-MS-MS) was performed according to
Wilm and Mann (15), and phosphopeptides were detected by
m/z Metabolic Cell Labeling--
COS-1 cells in 10-cm dishes were
transfected with pECE.HA-Ndr-WT. After 72 h the medium was changed
to phosphate-free Dulbecco's modified Eagle's medium containing 10%
dialyzed fetal calf serum and 1 mCi/plate of
32Pi (Amersham Pharmacia Biotech). After a
further 5 h the cells were stimulated with okadaic acid,
harvested, and HA-Ndr purified as described above.
Phosphoamino Acid Analysis and Phosphate Release--
Tryptic
phosphopeptides were separated by LC-MS and the
32P-phosphopeptides P1 and P4 identified by their molecular
masses (17). An aliquot (200 cpm) of each purified
32P-phosphopeptide was lyophilized and then hydrolyzed in
6M HCl containing 0.2 mg/ml bovine serum albumin at 110 °C for 45 min. The hydrolysate was separated by thin layer electrophoresis at pH
3.5 (18) and radioactivity detected using a PhosphorImager (Molecular
Dynamics). In parallel, 400 cpm of each 32P-phosphopeptide
was subjected to solid-phase Edman degradation using an automated model
477A sequenator (Applied Biosystems). Fractions from each cycle of
Edman degradation were lyophilized, redissolved in 50% acetonitrile,
and spotted onto a thin layer chromatography plate, before exposure to
a PhosphorImager screen.
Site-directed Mutagenesis--
The insert of the plasmid
pECE.HA-Ndr-WT was cloned between the KpnI and
XbaI sites of pcDNA3 (Invitrogen) to generate
pcDNA3.HA-Ndr-WT. Ser-281 and Thr-444 were mutagenized using
QuickChange (Stratagene).
Mapping of Regulatory Phosphorylation Sites in Ndr--
We
observed that the activity of both transfected and endogenous Ndr was
potently stimulated upon treatment of intact cells with okadaic acid
(OA) at concentrations that would result in specific inhibition of
protein phosphatase 2A (19). Moreover, in vitro incubation
of Ndr with purified protein phosphatase 2A resulted in a complete loss
of Ndr activity (data not shown). These findings prompted us to map the
regulatory phosphorylation sites in Ndr that are essential for its
activity. COS-1 cells expressing HA-Ndr were treated with OA or with
solvent alone, and HA-Ndr was then immunopurified using the 12CA5
monoclonal antibody. Approximately 1 µg of purified HA-Ndr was
digested with trypsin, and the resultant mixture of peptides was
analyzed by ESI-MS-MS in a
When HA-Ndr from control cells was analyzed in this way, only weak
phosphopeptide signals could be detected (Fig.
1A). In HA-Ndr from OA-treated
cells, however, the abundance of phosphopeptides was markedly increased
(Fig. 1B). The observed m/z of each of these
peaks could be accounted for by five Ndr-derived peptides, each of
which was ~79 Da heavier than would be expected for the nonphosphorylated state (Fig. 1C). The identities of several
of these phosphopeptides were also confirmed by partial sequencing (data not shown). The five phosphopeptides derive from two regions of
the Ndr polypeptide. The first group of phosphopeptides (P1, P2, and
P3) are from a region of the Ndr kinase domain that corresponds to the
activation-loop (or T-loop) of other kinases (Ndr amino acids
277-301). The second group of phosphopeptides (P4 and P5) come from
the carboxyl-terminal region of the Ndr polypeptide ~60 amino acids
COOH-terminal to the catalytic domain (Ndr amino acids 437-447). Each
of these regions contains three amino acids that could potentially be
phosphorylated (marked in bold in Fig. 1C). To precisely
locate each phosphorylation site, HA-Ndr was isolated from cells that
had been metabolically labeled with 32Pi prior
to OA treatment, and tryptic peptides were purified
chromatographically; one phosphopeptide from each region (P1 from Ndr
amino acids 277-294, and P4 from Ndr amino acids 437-446) was then
selected for further analysis. As shown in Fig. 1D,
phosphopeptide P1 gave rise exclusively to phosphoserine upon acid
hydrolysis, and released radioactivity in the fifth cycle of Edman
degradation, demonstrating phosphorylation of Ser-281. In contrast,
phosphopeptide P4 contained phosphothreonine, and released
32P in cycle 8 of Edman degradation, showing that Thr-444
is phosphorylated (Fig. 1E). These results demonstrate that
cell stimulation with OA results in the phosphorylation of two sites in
Ndr and that these two sites are Ser-281 and Thr-444.
Phosphorylation Stoichiometry of Ser-281 and Thr-444--
A
portion of the tryptic peptides from Fig. 1, A and
B, were analyzed by LC-MS to estimate the relative abundance
of phosphorylated and dephosphorylated forms of Ser-281- and
Thr-444-containing peptides. Assuming equal elution efficiency of
phospho- and dephospho-forms, both Ser-281 and Thr-444 in Ndr from
control cells were phosphorylated to a stoichiometry of ~0.1 mol/mol,
consistent with the fact that HA-Ndr from unstimulated cells has a low
but measurable level of basal activity (see Fig.
2). Upon OA treatment, Ser-281
phosphorylation rose to ~0.8 mol/mol, while Thr-444 phosphorylation
rose to ~0.5 mol/mol (data not shown).
Ndr Requires Phosphorylation on Ser-281 and Thr-444 for Its
Activity--
Ndr mutants were created in which either Ser-281 or
Thr-444 was replaced by alanine. The protein kinase activity of each of these mutants was measured following cell treatment with OA or with
solvent alone. HA-Ndr-WT was potently (~25-fold) stimulated by OA
(Fig. 2). Both the S281A and T444A mutants had markedly reduced basal
kinase activity but were still activated (15-20-fold) by OA. However,
combined mutation of the two sites (S281A/T444A) reduced basal activity
to near undetectable levels and abolished the ability of Ndr to be
stimulated by OA. Western blot analysis confirmed that the various
mutants were expressed at comparable levels (Fig. 2). These results
confirm that Ndr requires phosphorylation on Ser-281 and Thr-444 for
its activity.
We also attempted to create constitutively active mutants of Ndr by
replacing Ser-281 and/or Thr-444 with negatively charged amino acids.
S281D and S281E mutants had basal and OA-stimulated activities similar
to those of the S281A mutant, suggesting that steric constraints in
this region of the molecule are too tight to allow effective mimicry of
a phosphate group by a negatively charged amino acid side chain (data
not shown). T444D and T444E mutants had moderately (1.5-2-fold)
elevated basal kinase activity (data not shown).
Ser-281 and Thr-444 Are Conserved in Ndr-related
Kinases--
Comparison of the sequence of Ndr with those of the
closely related kinases LATS, Orb6, and Cot-1 shows that potential
phosphorylation sites corresponding to both Ser-281 and Thr-444 are
conserved throughout the family (Fig. 3).
Moreover, the sequences surrounding these sites are highly conserved.
It is therefore probable that Orb6, LATS and Cot-1 are also regulated
by phosphorylation on sites equivalent to Ser-281 and Thr-444 of Ndr.
Dbf2 also contains potential phosphorylation sites at positions
equivalent to Ser-281 and Thr-444 of Ndr; however the sequences
surrounding these sites are somewhat less well conserved (not
shown).
Evidence That Ndr Is Not a Target of PDK1--
Ser-281 of Ndr
shows significant homology to a site in several protein kinases that
are substrates for the phosphoinositide-dependent kinase
PDK1 (see "Discussion"). We therefore tested the possibility that
Ndr too might be a target of PDK1. Myc-tagged PDK1 was coexpressed with
HA-Ndr in HEK-293 cells, and Ndr was then immunoprecipitated and
assayed for kinase activity. PDK1 overexpression had very little effect
on HA-Ndr activity (Fig. 4A),
although it was readily detectable by Western blotting (Fig.
4B). In the same experiment, PDK1 caused a >20-fold
activation of
Several PDK1 substrates are activated when cells are exposed to insulin
or IGF-1. We investigated whether these ligands are able to activate
endogenous Ndr in HEK-293 cells. We found that endogenous Ndr was
activated ~15-fold by OA, but showed no response to either insulin or
IGF-1 (Fig. 4C). The same extracts used to measure Ndr
kinase activity in Fig. 4C were immunoblotted using a
phosphospecific antibody that recognizes phosphorylated Ser-473 of PKB
(which is similar to Thr-444 of Ndr). As expected, phosphorylation of
PKB Ser-473 was strongly induced by both insulin and IGF-1 (Fig.
4D). The lack of activation of Ndr by insulin or IGF-1 was confirmed using epitope-tagged Ndr overexpressed in HEK-293 cells (data
not shown). Since Ndr was not activated under conditions that promote
phosphorylation and activation of PKB, it would appear that the kinase
that activates Ndr is distinct from the kinase responsible for
phosphorylation of PKB.
In this paper, we have shown that the activity of Ndr protein
kinase is critically dependent on phosphorylation at two sites, Ser-281
and Thr-444. Based on these results, we predict that LATS, Orb6, Cot-1,
and possibly Dbf2 are regulated by phosphorylation on homologous
sites. Both Ser-281 and Thr-444 must be phosphorylated for full Ndr
activity, but phosphorylation of either site alone is sufficient for a
more limited degree of activity. Two of the kinases closely related to
Ndr, LATS and Dbf2, are already known to exist as
phosphoproteins, although their phosphorylation sites have not been
mapped (3, 6). Both LATS and Dbf2 are phosphorylated in a cell
cycle-dependent manner, as shown by cell cycle
stage-dependent changes in their mobility on SDS gels that
can be reversed by in vitro treatment with calf intestinal
phosphatase. Ndr protein kinase is the closest known relative of the
tumor suppressor LATS in mammalian cells, and several tissues and cell
types co-express Ndr and LATS. The high level of homology of these
kinases in regions targeted for phosphorylation in Ndr suggests the
possibility that they could be regulated by the same upstream kinase.
Ser-281 of Ndr shows homology to activation-loop phosphorylation sites
that are found in several members of the AGC subgroup of
serine/threonine kinases, such as PKB/Akt (20), p70 S6 kinase (11, 21),
SGK (22, 23), protein kinase C (24, 25), and cAMP-dependent
protein kinase (26). The activation-loop site in each of these kinases
is a substrate for PDK1. Based on sequence comparisons, Cheng et
al. (26) proposed a consensus phosphorylation motif for PDK1 as
Thr-Xaa-Cys-Gly-Thr-Xaa-Asp/Glu-Tyr-Xaa-Ala-Pro-Glu, where
Xaa is a hydrophobic residue, and the first Thr in the sequence is the
phosphoacceptor. The sequence around Ser-281 of Ndr is homologous to
this consensus in 9 out of 12 positions. Moreover, most PDK1 targets
contain a second phosphorylation site approximately 60 amino acids
carboxyl-terminal to the end of the kinase catalytic domain, which is
flanked by hydrophobic amino acids (consensus Phe-Xaa-Xaa-Phe-Ser/Thr-Phe/Tyr) and which, at least in the
case of PKB, is phosphorylated by a modified form of PDK1 (27). Thr-444 of Ndr shows similarity to this second motif both in terms of the
sequence surrounding it and in terms of its positioning within the
polypeptide chain. However, our results suggest that Ndr is not
phosphorylated by PDK1. One potential explanation for this could be an
unusual structural feature present in Ndr. As shown in Fig. 3, Ndr and
its close relatives contain an insert of ~40 amino acids between the
catalytic subdomains VII and VIII, which is absent from all other known
kinases. This insert interrupts the canonical kinase catalytic domain,
beginning COOH-terminally to the conserved "DFG" kinase motif and
ending directly NH2-terminal to Ser-281. The close
proximity of this domain to Ser-281 might influence the recognition of
Ser-281 by upstream kinases, such that phosphorylation by PDK1 is
prevented. Moreover, in Ndr this domain harbors a nuclear localization
signal so that in the cell, Ndr and PDK1 may be separated from each
other in distinct compartments (1). Taken together, our results suggest
that Ndr might be the target of an as-yet-unidentified nuclear
activation loop kinase that has a substrate specificity similar to, but
distinct from, PDK1. In addition, the stimulation of Ndr activity by OA
in intact cells, as well as the ability of protein phosphatase 2A to
inactivate Ndr in vitro, indicate that Ndr may be a
physiological substrate of protein phosphatase 2A.
We thank Renate Matthies for phosphopeptide
purification and phosphate release, Iwan Beuwink for help and advice in
metabolic cell labeling and detection of radioactivity in Sequenator
fractions, Dr. Nick Pullen for help with phosphoamino acid analysis,
and Jongsun Park for PDK1 and PKB expression plasmids. We thank Dr. Tom
Sturgill and Dr. Sauveur-Michel Maira for critical reading of the manuscript.
*
This work was supported by Krebsforschung Schweiz Grant KFS
269-1-1996 (to B. A. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The abbreviations used are:
PDK1, phosphoinositide-dependent kinase-1;
HA, hemagglutinin;
OA, okadaic acid;
ESI-MS-MS, electrospray ionization mass spectrometry;
LC-MS, liquid chromatography interfaced with electrospray mass
spectrometry;
WT, wild-type.
COMMUNICATION
Ndr Protein Kinase Is Regulated by Phosphorylation on Two
Conserved Sequence Motifs*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
PH-PKB (12). Immune complex kinase
assays for HA-Ndr and for endogenous Ndr were carried out as described
(10). HA-
PH-PKB was immunoprecipitated and assayed for kinase
activity in the same way as HA-Ndr, except that 50 µg (0.1 mg/ml)
cell extract was used, and the kinase substrate used was Crosstide
(GRPRTSSFAEG; 30 µM). Immunoblotting was carried out as
described (10), using monoclonal antibodies 12CA5 or 9E10 or a
polyclonal antibody against phosphorylated Ser-473 of PKB (New England Biolabs).
79 precursor ion scanning (16). The mass
spectra were acquired on an API 300 triple quadrupole mass spectrometer
(PE Sciex, Toronto, Ontario, Canada) equipped with a NanoESI source
(Protana, Odense, Denmark). To estimate phosphorylation stoichiometry,
peptides were fractionated by LC-MS (17). Phospho- and
dephosphopeptides were detected by extraction of the MS data for the
corresponding ions.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
79 precursor scan (16). This procedure
measures the mass:charge ratio (m/z) of each
peptide in the mixture that, upon fragmentation, liberates a species
with a m/z of
79 (corresponding to a single
phosphate group).

View larger version (39K):
[in a new window]
Fig. 1.
Mapping of regulatory phosphorylation sites
in Ndr protein kinase. A and B, ESI-MS-MS
79 precursor scan for phosphopeptides in HA-Ndr immunopurified from
control (A) or OA-treated (B) COS-1 cells.
Phosphopeptides whose m/z could be assigned to Ndr-derived
peptides are labeled P1 through P5. Most of these peptides were
detected in several different charged states, designated [M
2H]2
, [M
3H]3
, and so on. A
methionine residue in peptides P1 and P2 was found to be oxidized; this
oxidation presumably occurred during purification. P2 and P3 result
from trace chymotryptic contamination of the trypsin preparation, since
they both terminate with aromatic residues at the carboxyl-terminal
end. C, the phosphopeptides from Fig. 1B, which
derive from two regions of the Ndr polypeptide, are summarized with
potential phosphoacceptors in each peptide marked in bold. D
and E, phosphoamino acid analysis (upper panels)
and phosphate release (lower panels) of
32P-phosphopeptides P1 (D) and P4 (E)
purified from metabolically labeled, OA-treated COS-1 cells expressing
HA-Ndr. Positions of ninhydrin-stained phosphoamino acid standards are
shown above the upper panels. 32P release by
Edman degradation was detected by spotting sequenator fractions onto
thin layer chromatography plates, followed by exposure to a
PhosphorImager.

View larger version (32K):
[in a new window]
Fig. 2.
Phosphorylation of Ser-281 and Thr-444 is
required for Ndr activity. COS-1 cells expressing either wild-type
HA-Ndr or the indicated mutants were treated for 1 h with solvent
alone (open bars) or with 1 µM OA
(filled bars). HA-tagged kinases were then
immunoprecipitated and assayed for kinase activity (upper
panel). Data are the mean ± S.D. of duplicate
immunoprecipitations. In the lower panel, protein extracts
(10 µg) were analyzed by immunoblotting with 12CA5 to verify similar
expression levels of each Ndr construct.

View larger version (61K):
[in a new window]
Fig. 3.
Potential phosphorylation sites homologous to
Ser-281 and Thr-444 of Ndr are present in several Ndr-related
kinases. In the upper panel, the catalytic domain
homologies (amino acid identity) between Ndr and the kinases LATS,
Orb6, and Cot-1 are shown. In the lower panel, the sequences
surrounding Ser-281 and Thr-444 of Ndr are aligned with the
corresponding regions of LATS, Orb6, and Cot-1. Identical amino acids
are shown in white on a black background, and conservative
substitutions are shown in black on a gray background.
Roman numerals denote protein kinase catalytic subdomains
(28).
PH-PKB, an established PDK1 substrate (12).
Immunoprecipitated myc-PDK1 also failed to transfer phosphate to a
complex of GST-Ndr K118A with Ca2+/S100B in
vitro (10), although it autophosphorylated efficiently (data not
shown).

View larger version (41K):
[in a new window]
Fig. 4.
Evidence that Ndr is not a target of
PDK1. A, 293 cells were transfected with plasmids
encoding HA-Ndr (5 µg DNA) or HA-
PH-PKB (5 µg DNA), together
with 0, 1, or 5 µg of plasmid encoding myc-PDK1 as indicated below
the graph. After transfection, cells were serum-starved for 24 h
and then HA-tagged kinases were immunoprecipitated and assayed for
kinase activity. Bars represent mean ± S.D. of
duplicate immunoprecipitations. B, protein extracts (10 µg) from Fig. 4A were immunoblotted with 12CA5
(upper panel) to verify expression of HA-Ndr and
HA-
PH-PKB or with 9E10 (lower panel) to verify expression
of myc-PDK1. C, 293 cells were serum-starved and were then
left untreated or were treated with insulin or IGF-1 (left
panel). Alternatively, asynchronously growing 293 cells were
treated with solvent alone or with OA (right panel).
Endogenous Ndr activity was then determined in each cell extract by
immune complex kinase assay; bars represent mean ± S.D. of duplicate immunoprecipitations. D, the cell extracts
used in Fig. 4C (30 µg/lane) were immunoblotted with an
antibody that recognizes the activated form of PKB, phosphorylated on
Ser-473.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed. Tel.: 41-61-697-40-46;
Fax: 41-61-697-39-76; E-mail: hemmings@fmi.ch.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Millward, T.,
Cron, P.,
and Hemmings, B. A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
5022-5026 2.
St. John, M. A.,
Tao, W.,
Fei, X.,
Fukumoto, R.,
Carcangiu, M. L.,
Brownstein, D. G.,
Parlow, A. F.,
McGrath, J.,
and Xu, T.
(1999)
Nat. Genet.
21,
182-186[CrossRef][Medline]
[Order article via Infotrieve]
3.
Tao, W.,
Zhang, S.,
Turenchalk, G. S.,
Stewart, R. A.,
St John, M. A.,
Chen, W.,
and Xu, T.
(1999)
Nat. Genet.
21,
177-181[CrossRef][Medline]
[Order article via Infotrieve]
4.
Verde, F.,
Wiley, D. J.,
and Nurse, P.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7526-7531 5.
Jaspersen, S. L.,
Charles, J. F.,
Tinker-Kulberg, R. L.,
and Morgan, D. O.
(1998)
Mol. Biol. Cell
9,
2803-2817 6.
Toyn, J. H.,
and Johnston, L. H.
(1994)
EMBO J.
13,
1103-1113[Medline]
[Order article via Infotrieve]
7.
Yarden, O.,
Plamann, M.,
Ebbole, D. J.,
and Yanofsky, C.
(1992)
EMBO J.
11,
2159-2166[Medline]
[Order article via Infotrieve]
8.
Seed, B.,
and Aruffo, A.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
3365-3369 9.
Chen, C.,
and Okayama, H.
(1987)
Mol. Cell. Biol.
7,
2745-2752 10.
Millward, T. A.,
Heizmann, C. W.,
Schafer, B. W.,
and Hemmings, B. A.
(1998)
EMBO J.
17,
5913-5922[CrossRef][Medline]
[Order article via Infotrieve]
11.
Pullen, N.,
Dennis, P. B.,
Andjelkovic, M.,
Dufner, A.,
Kozma, S. C.,
Hemmings, B. A.,
and Thomas, G.
(1998)
Science
279,
707-710 12.
Andjelkovic, M.,
Maira, S. M.,
Cron, P.,
Parker, P. J.,
and Hemmings, B. A.
(1999)
Mol. Cell. Biol.
19,
5061-5072 13.
Bensadoun, A.,
and Weinstein, D.
(1976)
Anal. Biochem.
70,
241-250[CrossRef][Medline]
[Order article via Infotrieve]
14.
Shevchenko, A.,
Wilm, M.,
Vorm, O.,
and Mann, M.
(1996)
Anal. Chem.
68,
850-858[Medline]
[Order article via Infotrieve]
15.
Wilm, M.,
and Mann, M.
(1996)
Anal. Chem.
68,
1-8[Medline]
[Order article via Infotrieve]
16.
Carr, S. A.,
Huddelstone, M. J.,
and Annan, R. S.
(1996)
Anal. Biochem.
239,
180-192[CrossRef][Medline]
[Order article via Infotrieve]
17.
Krieg, J.,
Hartmann, S.,
Vicentini, A.,
Gläsner, W.,
Hess, D.,
and Hofsteenge, J.
(1998)
Mol. Biol. Cell
9,
301-309 18.
Duclos, B.,
Marcandier, S.,
and Cozzone, A. J.
(1991)
Methods Enzymol.
201,
10-21[Medline]
[Order article via Infotrieve]
19.
Favre, B.,
Turowski, P.,
and Hemmings, B. A.
(1997)
J. Biol. Chem.
272,
13856-13863 20.
Alessi, D. R.,
Deak, M.,
Casamayor, A.,
Caudwell, F. B.,
Morrice, N.,
Norman, D. G.,
Gaffney, P.,
Reese, C. B.,
MacDougall, C. N.,
Harbison, D.,
Ashworth, A.,
and Bownes, M.
(1997)
Curr. Biol.
7,
776-789[CrossRef][Medline]
[Order article via Infotrieve]
21.
Alessi, D. R.,
Kozlowski, M. T.,
Weng, Q. P.,
Morrice, N.,
and Avruch, J.
(1998)
Curr. Biol.
8,
69-81[CrossRef][Medline]
[Order article via Infotrieve]
22.
Kobayashi, T.,
and Cohen, P.
(1999)
Biochem. J.
339,
319-328
23.
Park, J.,
Leong, M. L.,
Buse, P.,
Maiyar, A. C.,
Firestone, G. L.,
and Hemmings, B. A.
(1999)
EMBO J.
18,
3024-3033[CrossRef][Medline]
[Order article via Infotrieve]
24.
Dutil, E. M.,
Toker, A.,
and Newton, A. C.
(1998)
Curr. Biol.
8,
1366-1375[CrossRef][Medline]
[Order article via Infotrieve]
25.
Le Good, J. A.,
Ziegler, W. H.,
Parekh, D. B.,
Alessi, D. R.,
Cohen, P.,
and Parker, P. J.
(1998)
Science
281,
2042-2045 26.
Cheng, X.,
Ma, Y.,
Moore, M.,
Hemmings, B. A.,
and Taylor, S. S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9849-9854 27.
Balendran, A.,
Casamayor, A.,
Deak, M.,
Paterson, A.,
Gaffney, P.,
Currie, R.,
Downes, C. P.,
and Alessi, D. R.
(1999)
Curr. Biol.
9,
393-404[CrossRef][Medline]
[Order article via Infotrieve]
28.
Hanks, S. K.,
and Hunter, T.
(1995)
FASEB J.
9,
576-596[Abstract]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. M. Jansen, M. F. Barry, C. K. Yoo, and E. L. Weiss Phosphoregulation of Cbk1 is critical for RAM network control of transcription and morphogenesis J. Cell Biol., December 4, 2006; 175(5): 755 - 766. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Suzuki, T. Ogura, and H. Esumi NDR2 Acts as the Upstream Kinase of ARK5 during Insulin-like Growth Factor-1 Signaling J. Biol. Chem., May 19, 2006; 281(20): 13915 - 13921. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Stegert, A. Hergovich, R. Tamaskovic, S. J. Bichsel, and B. A. Hemmings Regulation of NDR Protein Kinase by Hydrophobic Motif Phosphorylation Mediated by the Mammalian Ste20-Like Kinase MST3 Mol. Cell. Biol., December 15, 2005; 25(24): 11019 - 11029. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hergovich, S. J. Bichsel, and B. A. Hemmings Human NDR Kinases Are Rapidly Activated by MOB Proteins through Recruitment to the Plasma Membrane and Phosphorylation Mol. Cell. Biol., September 15, 2005; 25(18): 8259 - 8272. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. He, K. Emoto, X. Fang, N. Ren, X. Tian, Y.-N. Jan, and P. N. Adler Drosophila Mob Family Proteins Interact with the Related Tricornered (Trc) and Warts (Wts) Kinases Mol. Biol. Cell, September 1, 2005; 16(9): 4139 - 4152. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. He, X. Fang, K. Emoto, Y.-N. Jan, and P. N. Adler The Tricornered Ser/Thr Protein Kinase Is Regulated by Phosphorylation and Interacts with Furry during Drosophila Wing Hair Development Mol. Biol. Cell, February 1, 2005; 16(2): 689 - 700. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Bichsel, R. Tamaskovic, M. R. Stegert, and B. A. Hemmings Mechanism of Activation of NDR (Nuclear Dbf2-related) Protein Kinase by the hMOB1 Protein J. Biol. Chem., August 20, 2004; 279(34): 35228 - 35235. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kottom and A. H. Limper Pneumocystis carinii Cell Wall Biosynthesis Kinase Gene CBK1 Is an Environmentally Responsive Gene That Complements Cell Wall Defects of cbk-Deficient Yeast Infect. Immun., August 1, 2004; 72(8): 4628 - 4636. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Devroe, H. Erdjument-Bromage, P. Tempst, and P. A. Silver Human Mob Proteins Regulate the NDR1 and NDR2 Serine-Threonine Kinases J. Biol. Chem., June 4, 2004; 279(23): 24444 - 24451. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Stegert, R. Tamaskovic, S. J. Bichsel, A. Hergovich, and B. A. Hemmings Regulation of NDR2 Protein Kinase by Multi-site Phosphorylation and the S100B Calcium-binding Protein J. Biol. Chem., May 28, 2004; 279(22): 23806 - 23812. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Hou, D. A. Guertin, and D. McCollum Initiation of Cytokinesis Is Controlled through Multiple Modes of Regulation of the Sid2p-Mob1p Kinase Complex Mol. Cell. Biol., April 15, 2004; 24(8): 3262 - 3276. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Wansink, R. E. M. A. van Herpen, M. M. Coerwinkel-Driessen, P. J. T. A. Groenen, B. A. Hemmings, and B. Wieringa Alternative Splicing Controls Myotonic Dystrophy Protein Kinase Structure, Enzymatic Activity, and Subcellular Localization Mol. Cell. Biol., August 15, 2003; 23(16): 5489 - 5501. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kamikubo, A. Takaori-Kondo, T. Uchiyama, and T. Hori Inhibition of Cell Growth by Conditional Expression of kpm, a Human Homologue of Drosophila warts/lats Tumor Suppressor J. Biol. Chem., May 9, 2003; 278(20): 17609 - 17614. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Tamaskovic, S. J. Bichsel, H. Rogniaux, M. R. Stegert, and B. A. Hemmings Mechanism of Ca2+-mediated Regulation of NDR Protein Kinase through Autophosphorylation and Phosphorylation by an Upstream Kinase J. Biol. Chem., February 21, 2003; 278(9): 6710 - 6718. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Adeyinka, E. Emberley, Y. Niu, L. Snell, L. C. Murphy, H. Sowter, C. C. Wykoff, A. L. Harris, and P. H. Watson Analysis of Gene Expression in Ductal Carcinoma in Situ of the Breast Clin. Cancer Res., December 1, 2002; 8(12): 3788 - 3795. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Mah, J. Jang, and R. J. Deshaies Protein kinase Cdc15 activates the Dbf2-Mob1 kinase complex PNAS, June 7, 2001; (2001) 141098998. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Tan, K. T. Seow, L. Lim, and T. Leung Intermolecular and Intramolecular Interactions Regulate Catalytic Activity of Myotonic Dystrophy Kinase-Related Cdc42-Binding Kinase {alpha} Mol. Cell. Biol., April 15, 2001; 21(8): 2767 - 2778. [Abstract] [Full Text] |
||||
![]() |
S. Bidlingmaier, E. L. Weiss, C. Seidel, D. G. Drubin, and M. Snyder The Cbk1p Pathway Is Important for Polarized Cell Growth and Cell Separation in Saccharomyces cerevisiae Mol. Cell. Biol., April 1, 2001; 21(7): 2449 - 2462. [Abstract] [Full Text] |
||||
![]() |
W. Geng, B. He, M. Wang, and P. N. Adler The tricornered Gene, Which Is Required for the Integrity of Epidermal Cell Extensions, Encodes the Drosophila Nuclear DBF2-Related Kinase Genetics, December 1, 2000; 156(4): 1817 - 1828. [Abstract] [Full Text] |
||||
![]() |
A. S. Mah, J. Jang, and R. J. Deshaies Protein kinase Cdc15 activates the Dbf2-Mob1 kinase complex PNAS, June 19, 2001; 98(13): 7325 - 7330. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||